“Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s240, https://doi.org/10.25251/skin.7.supp.240.